Published in final edited form as:

J Nat Prod. 2008 March ; 71(3): 390–395.

Potential Anticancer Activity of Naturally Occurring and Semi-Synthetic Derivatives of Aculeatins A and B from *Amomum aculeatum*[#]

Young-Won Chin[†], Angela A. Salim[†], Bao-Ning Su[†], Qiuwen Mi[‡], Hee-Byung Chai[†], Soedarsono Riswan[§], Leonardus B. S. Kardono[⊥], Agus Ruskandi[§], Norman R. Farnsworth[‡], Steven M. Swanson[‡], and A. Douglas Kinghorn^{†*}

[†]*Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210*

[‡]*Program for Collaborative Research in the Pharmaceutical Sciences and Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612*

[§]*Herbarium Bogoriense, Research Center for Biology, Indonesian Institute of Science, Bogor 16122, Indonesia*

[⊥]*Research Center for Chemistry, Indonesian Institute of Science, Tangerang 15310, Indonesia*

Abstract

Activity-guided fractionation of hexanes- and CHCl₃-soluble extracts of *Amomum aculeatum* leaves, collected in Indonesia, led to the isolation of three new dioxadispiroketal-type (**3–5**) and two new oxadispiroketal-type (**6** and **7**) derivatives. Nine semi-synthetic derivatives (**1a–1h** and **2a**) of the parent compounds, aculeatins A (**1**) and B (**2**), were prepared. All isolates and semi-synthetic compounds were tested against a small panel of human cell lines. Of these, aculeatin A (**1**; ED₅₀ 0.2–1.0 μM) was found to be among the most cytotoxic of the compounds tested, and was further evaluated in an in vivo hollow fiber assay, and found to be active against MCF-7 (human breast cancer) cells implanted intraperitoneally at doses of 6.25, 12.5, 25, and 50 mg/kg. However, when **1** was tested using P388 lymphocytic leukemia and human A2780 ovarian carcinoma in vivo models, it was deemed to be inactive at the doses used.

Amomum aculeatum Roxb. (Zingiberaceae) is a herbaceous plant, distributed in Indonesia, Malaysia, and Papua New Guinea, and has been used as a folk medicine for the treatment of fever and malaria.¹ In initial phytochemical work on this species, the 1,7-dioxadispiro[5.1.5.2] pentadecane-type compounds, aculeatins A–D, were characterized and found to exhibit antibacterial, antiprotozoal, and cytotoxic activities.^{2,3} Of these compounds, aculeatins A, B, and D have been chemically synthesized due to their unusual structures and interesting bioactivities, and, through enantioselective synthetic methods, the absolute configurations of these three substances were resolved definitively.^{4–9}

In a preliminary short report, we have described the isolation, structural characterization, and cytotoxicity testing of aculeatols A–D, four C-9 hydroxylated analogs, from the leaves of *A. aculeatum*.¹⁰ Aculeatols A–D are of structural and spectroscopic interest since they contain

[#]Dedicated to Dr. G. Robert Pettit of Arizona State University for his pioneering work on bioactive natural products.

*To whom correspondence should be addressed. Tel.: +1 614 247 8094. Fax: +1 614 247 8081. E-mail: kinghorn.4@osu.edu.

five stereocenters as opposed to only three in the parent compounds, aculeatins A (**1**) and B (**2**), which were also present in the plant samples investigated.¹⁰

In the present study, as part of a collaborative approach to the discovery of new anticancer agents of plant origin,¹¹ we have delved more fully into the potential as cancer chemotherapeutic agents of compounds based on the unusual 1,7-dioxadispiro[5.1.5.2]pentadecane chemotype. Five new constituents (**3–7**) of *A. aculeatum* have been isolated and characterized, and are reported herein. Since aculeatins A (**1**) and B (**2**) were isolated in reasonably high yields, these compounds have been derivatized to produce compounds **1a–1h** and **2a**, respectively, in an attempt to generate biologically potent analogs. Isolates (**3–7**) and derivatives (**1a–1h** and **2a**) were then evaluated against a small panel of human cancer cell lines. In addition, follow up in vivo testing has been performed on aculeatin A (**1**) in an in vivo hollow fiber assay, and also in P388 lymphocytic murine leukemia and human A2780 ovarian carcinoma in vivo models.

Results and Discussion

By bioactivity-guided fractionation of the hexanes and chloroform-soluble extract of *A. aculeatum* leaves, using MCF-7 (human breast cancer) cells as a monitor, three new 1,7-dioxadispiro[5.1.5.2]pentadecane-type compounds (**3–5**) and two new 1-oxaspiro[4,5]decane-type compounds (**6** and **7**) were isolated and characterized.

Compound **3** was isolated as a yellow oil and displayed a sodiated molecular ion peak at m/z 413.2668 in the HRESIMS, corresponding to an elemental formula of $C_{24}H_{38}O_4Na$ (calcd for $C_{24}H_{38}O_4Na$, 413.2668). The ^1H NMR spectrum of **3** was closely comparable to that of aculeatin B (**2**),^{2,10} suggesting the presence of a 1,7-dioxadispiro[5.1.5.2]pentadeca-9,12-dien-11-one unit from signals in the range δ_H 1.28 to 6.99 and a long-chain aliphatic group from resonances between δ_H 0.88 and 1.47 (Table 1). However, the signals of **3** at δ_H 3.85 (1H, tt, $J = 11.2, 4.4$ Hz, H-4) and 3.36 (1H, m, H-2) appeared in a more upfield region when compared with analogous signals of aculeatin B [H-4 (δ_H 4.35), and H-2 (δ_H 3.86)]. These differences suggested that compound **3** has a different configuration at the C-4 position from aculeatin B (**2**). The coupling constants of 11.2 and 4.4 Hz for H-4 implied an axial position of this proton in the cyclohexane ring system, as opposed to the equatorial orientation in **2** (3.0 Hz, H-4).¹⁰ From the 2D NOESY data of **3**, it was found that H-4 exhibited NOE correlations with H-2 and H-15b (Figure 1), which showed the same orientation for both H-2 and H-4, and was used to establish the *R* and *S* configurations of C-2 and C-4, respectively. The configuration of the C-6 position was confirmed as *S* by the observation of a NOE correlation between H-2 and H-15a. When all of the spectroscopic data were taken into account, the structure of compound **3** was determined as *2R*,4S*,6S*-4*-hydroxy-2-undecyl-1,7-dioxadispiro[5.1.5.2]pentadeca-9,12-dien-11-one, and this isolate has been named aculeatin E.

The molecular formula of compound **4** was assigned as $C_{24}H_{38}O_4$, and was inferred from a sodiated molecular ion peak at m/z 413.2672 (calcd for $C_{24}H_{38}O_4Na$, 413.2668) in the HRESIMS. The ^1H NMR spectrum of **4** disclosed resonances at δ_H 6.86 (1H, dd, $J = 10.0, 2.9$ Hz, H-13), 6.77 (1H, dd, $J = 9.9, 2.9$ Hz, H-9), 6.15 (1H, dd, $J = 10.0, 1.8$ Hz, H-12), 6.11 (1H, dd, $J = 9.9, 1.8$ Hz, H-10), 4.13 (2H, m, H-2 and H-4), 2.37 (1H, m, H-14a), 2.24 (1H, m, H-15a), 2.00 (3H, m, H-5a, H-14b, and H-15b), 1.94 (1H, m, H-5b), 1.80 (1H, brd, $J = 13.1$ Hz, H-3a), 1.50 (2H, m, H-16), 1.43 (1H, m, H-17a), and 1.41 (1H, dd, $J = 13.1, 2.6$ Hz, H-3b), assignable to the same dioxadispiroketal-type skeleton as aculeatin A (**1**).² Comparison of the ^1H and ^{13}C NMR chemical shifts of **4** with those of aculeatin A indicated that both compounds have identical carbon skeletons. From detailed NMR assignments, the relative configurations at the chiral carbons in **4** were confirmed as being the same as aculeatin A (**1**) by the observation of correlations in several 2D NMR (^1H - ^1H COSY, HSQC, HMBC, and

NOESY) experiments. The only difference was observed in the respective molecular formula of these substances. As shown by the MS data, compound **4** has two less methylene units in the aliphatic side chain when compared with aculeatin A (C₂₆H₄₂O₄). Thus, the structure of **4** (aculeatin F) was determined as 2*R**,4*R**,6*R**-4-hydroxy-2-undecyl-1,7-dioxadispiro[5.1.5.2]pentadec-9,12-dien-11-one.

The ¹H NMR spectroscopic data (Table 1) of compound **5** exhibited three oxymethine signals at δ_H 4.38 (1H, m, H-4), 3.93 (1H, dd, *J* = 8.7, 5.4 Hz, H-9), and 3.91 (1H, m, H-2), two olefinic proton signals at δ_H 6.61 (1H, d, *J* = 10.0 Hz, H-13) and 5.99 (1H, d, *J* = 10.0 Hz, H-12), and one methylene signal at δ_H 2.73 (2H, m, H-10), attributable to an aculeatol-type structure.¹⁰ In addition, it was found that the ¹³C NMR spectroscopic data of **5** were generally comparable to those of aculeatol D.¹⁰ The ¹³C NMR chemical shifts at δ_C 69.7 (C-2) and 34.6 (C-15) were supportive of the configuration of C-6 as being *S*.¹⁰ The coupling constants of H-9 (8.7 and 5.4 Hz) and H-5a (13.9 and 3.1 Hz), and NOE correlations between H-2/H-15a, H-9/H-14a, and H-13/H-14b in the 2D NOESY spectrum of **5**, suggested that the relative configurations at the other chiral centers in this structure are the same as those of aculeatol D.¹⁰ The distinction between compound **5** and aculeatol D is in the length of the alkyl side chain at C-2, as shown in the molecular formula of C₂₆H₄₄O₅ in **5** compared with C₂₄H₄₀O₅ for aculeatol D. Therefore, compound **5** (aculeatol E) was elucidated as 2*R**,4*R**,6*S**,8*R**,9*S**-4,9-dihydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5.2]pentadec-12-en-11-one.

The HRESIMS of **6** provided a sodiated molecular ion peak at *m/z* 457.3294 [M+Na]⁺, suggesting C₂₇H₄₆O₄ to be its molecular formula. The ¹H NMR spectrum of compound **6** exhibited resonances at δ_H 6.85 (1H, dd, *J* = 10.2, 2.7 Hz, H-10), 6.78 (1H, dd, *J* = 10.0, 2.7 Hz, H-6), 6.17 (1H, d, *J* = 10.0 Hz, H-9), 6.13 (1H, d, *J* = 10.0 Hz, H-7), 2.39 (1H, m, H-4a), 2.34 (1H, m, H-3a), 2.15 (1H, m, H-3b), and 2.07 (1H, m, H-4b), due to the presence of an oxaspiro[4,5]deca-6,9-dien-8-one unit, which has not been described in the literature to date (Table 2). From the remaining proton signals, only one oxymethine proton at δ_H 3.84 was observed when compared with two oxymethines present in aculeatin A (**1**), suggesting that the cyclohexane ring of a dioxadispiroketal-type compound has been cleaved in compound **6**. This assumption was supported by the observed HMBC correlation between the methoxy protons at δ_H 3.32 and the spiro carbon at δ_C 111.6 (C-2), instead of a correlation between H-14 and C-2 as exhibited by aculeatin-type compounds.^{2,10} The proton resonance signals at δ_H 2.39 and 2.07 (H-4) exhibited three-bond correlations with C-6 and C-10, respectively, which enabled the H-3 and H-4 signals to be assigned unambiguously. The preparation of Mosher ester derivatives of **6** was used to provide the absolute configuration of C-12 as *R*, based on the differences Δδ_{*R-S*} +0.081 (H11a), +0.049 (H-11b), and -0.014 (H-13a) between the (*R*)-MTPA and (*S*)-MTPA esters of **6**.^{12–15} Although the NOESY correlations of δ_H 6.82 (H-10) to 2.36 (H-4a) and 3.32 (OMe), and δ_H 6.75 (H-6) to 2.04 (H-4b) and 1.67 (H-11b) were observed, those correlations were not sufficient to demonstrate the relative configuration at the C-2 position. Thus, compound **6** (amomol A) was determined structurally as 2*S*,12*R*-2-(2-hydroxyheptadecyl)-2-methoxy-1-oxaspiro[4,5]deca-6,9-dien-8-one.

Compound **7** gave the same molecular formula (C₂₇H₄₆O₄) as compound **6**, and these compounds showed a close resemblance in their ¹H and ¹³C NMR spectroscopic data (Table 2). Furthermore, by analysis of the 2D NMR (¹H-¹H COSY, HSQC, HMBC, and NOESY) spectroscopic data, it was evident that the relative configuration of the 2-methoxy-1-oxaspiro[4,5]deca-6,9-dien-8-one unit of compound **7** was identical to that of **6**. On preparing *R*- and *S*-MTPA esters of compound **7**, the absolute configuration of C-12 in the alkyl side chain was established as *R*, the same configuration as in compound **6**. Since these two similar compounds were able to be separated on non-chiral HPLC column and their optical rotations are of the opposite signs, the configuration of C-2 in compounds **6** and **7** was inferred as being opposite, suggesting that these compounds are isomers. Therefore, the structure of **7** (amomol B) was

also designated as 2ξ,12*R*-2-(2-hydroxyheptadecyl)-2-methoxy-1-oxaspiro[4,5]deca-6,9-dien-8-one.

All isolated compounds were evaluated for their cytotoxic activity using a small panel of human cancer cell lines and their cytotoxic activities are summarized in Table 3.^{16,17} It was found that the five new compounds **3–7** were cytotoxic against the human cancer cell lines in which they were evaluated and comparable in potency to the parent compounds, aculeatins A (**1**) and B (**2**). Since aculeatin A (**1**) was isolated in a large quantity in the present study and exhibited potent cytotoxic activity, modifications in the structure of this parent compound were performed in an attempt to develop more active analogs. Eight semi-synthetic compounds **1a–1h** from aculeatin A, and aculeatin B acetate, **2a**, were synthesized. Modification of the free hydroxy group at C-4 position in aculeatin A (**1**) resulted in decreased cytotoxic activities for these compounds, as shown in Table 3. Likewise, the same cytotoxic trend was evident for aculeatin B (**2**) even though only one analog (**2a**) was tested in the present study. Thus, a free hydroxy group at the C-4 position in aculeatins A (**1**) and B (**2**) seems to be necessary for the elicitation of potent cytotoxic activity within this compound group.

Aculeatin A (**1**) was chosen for follow-up evaluation in an in vivo hollow fiber assay^{18–21} due to its cytotoxicity in the human cancer cell panel and its availability in a reasonably large quantity. This procedure is used as a secondary bioassay in our program on the discovery of natural product anticancer agents, since it is predictive of efficacy in follow-up in vivo assays and does not consume much test compound.^{20,21} Aculeatin A (**1**) inhibited the growth of the MCF-7 cell line (10–60%), propagated in hollow fibers via the intraperitoneal site, in the dose range 6.25–50 mg/kg (Figure 2). However, this compound was inactive when evaluated against the Lu1 (human lung cancer) and LNCaP (human prostate cancer) cells implanted at the intraperitoneal site at the same dose range (Figure S1, Supporting Information). Moreover, compound **1** was not active against any of the three cell lines used when implanted subcutaneously (dose range 6.25–50 mg/kg). When aculeatin A (**1**) was assessed in the in vivo P388 lymphocytic leukemia model,^{22,23} by intraperitoneal injection (15 mg/kg/injection), it was found to be inactive (T/C = 122%) in this model. Furthermore, compound **1** was inactive in a human A2780S ovarian carcinoma xenograft mouse model,^{24,25} and gave 0.4 log cell kill at 3 mg/kg/injection. Accordingly, it seems that compounds of the 1,7-dioxadispiro[5.1.5.2]pentadec-12-en-11-one structural type should only be investigated further as potential anticancer agents as low priority leads. However, owing to the cytotoxic potency of aculeatin A (**1**) against the MCF-7 cell line, and its efficacy against MCF-7 cells in hollow fibers, it may be worth performing a xenograft study on **1** with this same model.

Experimental Section

General Experimental Procedures

Optical rotations were measured using a Perkin-Elmer 241 automatic polarimeter. UV spectra were obtained with a Perkin-Elmer UV/vis lambda 10 spectrometer. IR spectra were run on a Nicolet Protege 460 FT-IR spectrophotometer. NMR spectroscopic data were recorded at room temperature using a Bruker DRX-400 spectrometer. Chemical shifts were reported as ppm with reference to the residual solvent or tetramethylsilane (TMS). Electrospray ionization (ESI) mass spectrometric analyses were obtained on a 3-tesla Finnigan FTMS-2000 Fourier transform mass spectrometer. A SunFire™ PrepC₁₈OBD™ column (5 μm, 150×19 mm i.d., Waters, Milford, MA) and a SunFire™ PrepC₁₈ guard column (5 μm, 10×19 mm i.d., Waters) were used for preparative HPLC, along with two Waters 515 HPLC pumps and a Waters 2487 dual λ absorbance detector (Waters). Column chromatography was carried out with Purasil® (230–400 mesh, Whatman, Clifton, NJ) and Sephadex LH-20 (Sigma, St. Louis, MO). Analytical thin-layer chromatography (TLC) was performed on precoated 250 μm thickness Partisil® K6F (Whatman) glass plates, while preparative thin-layer chromatography was

conducted on precoated 20×20 cm, 500 μ m Partisil® K6F (Whatman) glass plates. Semi-synthetic reagents were purchased from Sigma (St. Louis, MO). All solvents used for chromatographic separations were purchased from Fisher Scientific (Fair Lawn, NJ).

Plant Material

The leaves of *A. aculeatum* Roxb. were collected at Gunung Kancana, West Java, Indonesia, in August, 2003. The plant was identified by S. R. and A. R. A voucher specimen (SR-CJR 8) has been deposited at the Herbarium Bogoriense, Bogor, Indonesia.

Extraction and Isolation

The dried and milled leaves (803 g) of *A. aculeatum* were extracted with MeOH (3×1.5 L) overnight at room temperature. The solvent was evaporated in vacuo to afford a concentrated MeOH extract, which was then diluted with H₂O (0.9 L) to give an aqueous MeOH extract (1.0 L). This aqueous extract was partitioned in turn with hexanes (3×1.0 L), CHCl₃ (3×1.0 L), and EtOAc (3×1.0 L), to afford dried hexanes (10 g), CHCl₃ (2.1 g), EtOAc (6.6 g) and H₂O-soluble (21 g) residues. The hexanes- and CHCl₃-soluble extracts exhibited significant cytotoxicity against a human breast cancer cell line (MCF-7). Accordingly, the hexanes (ED₅₀ = 1.0 μ g/mL) and CHCl₃ (ED₅₀ = 1.2 μ g/mL) extracts were combined and subjected to silica gel column chromatography (10 × 40 cm, 230–400 mesh), eluted with pure CHCl₃ initially, then with a gradient mixture of CHCl₃–MeOH (100:1 to 1:1), to give eight fractions (F01–F08). These fractions were evaluated in the MCF-7 cell line, and the ED₅₀ (μ g/mL) values were >20, 0.3, 0.1, 0.9, 1.2, 5.0, 8.7, >20, respectively. Fraction F02 (3.5 g) was chromatographed on a silica gel column (4 × 45 cm) eluted with hexanes–EtOAc–MeOH (50:10:1) to give aculeatin A¹⁰ (**1**, 300 mg) and aculeatin B¹⁰ (**2**, 12 mg). During purification of a portion (40 mg) of crude aculeatin A (300 mg) using HPLC separation (MeCN–H₂O = 90:10, 8 mL/min), aculeatin F (**4**, 10 mg, *t*_R 20 min) was isolated. Fraction F03 (1.25 g) was also subjected to silica gel chromatography (2.5 × 45 cm) eluted with hexane–EtOAc–MeOH (30:15:1 to 30:15:2) to give nine subfractions (F0301 – 0309). The constituents of subfraction F0306 were further purified by HPLC using a reversed-phase C₁₈ column (H₂O–MeOH 85%–100% in 60 min) to furnish **3** (2.1 mg, *t*_R 24.6 min), **5** (1.3 mg, *t*_R 35.4 min), and a mixture of **6** and **7** (10.0 mg, *t*_R 57.5 min). Repetitive HPLC separation of this mixture using the same conditions afforded compounds **6** (4.6 mg, *t*_R 56.8 min) and **7** (3.2 mg, *t*_R 57.7 min).

Aculeatin E (**3**)

yellow oil; $[\alpha]_D^{22} +5.1$ (*c* 0.1, CHCl₃); UV (MeOH) $\lambda_{\max}$ (log ϵ) 230 (4.18) nm; IR (film) $\nu_{\max}$ 3440, 2923, 1671, 1634, 1080, 1014 cm^{−1}; ¹H NMR (CDCl₃, 400 MHz) and ¹³C NMR (CDCl₃, 100 MHz), see Table 1; HRESIMS *m/z* 413.2668 [M+Na], (calcd for C₂₄H₃₈O₄Na, 413.2668).

Aculeatin F (**4**)

yellow oil; $[\alpha]_D^{22} -5.0$ (*c* 0.4, CHCl₃); UV (MeOH) $\lambda_{\max}$ (log ϵ) 230 (4.27) nm; IR (film) $\nu_{\max}$ 3442, 2921, 1671, 1634, 1080, 1014 cm^{−1}; ¹H NMR (CDCl₃, 400 MHz) δ 6.86 (1H, dd, *J* = 10.0, 2.9 Hz, H-13), 6.77 (1H, dd, *J* = 9.9, 2.9 Hz, H-9), 6.15 (1H, dd, *J* = 10.0, 1.8 Hz, H-12), 6.11 (1H, dd, *J* = 9.9, 1.8 Hz, H-10), 4.13 (2H, m, H-2 and H-4), 2.37 (1H, m, H-14a), 2.24 (1H, m, H-15a), 2.00 (3H, m, H-5a, H-14b, and H-15b), 1.94 (1H, m, H-5b), 1.80 (1H, brd, *J* = 13.1 Hz, H-3a), 1.50 (2H, m, H-16), 1.43 (1H, m, H-17a), 1.41 (1H, dd, *J* = 13.1, 2.6 Hz, H-3b), 1.30 (1H, m, H-17b), 1.23–1.27 (16H, m, H-18 to H-25), 0.88 (3H, t, *J* = 6.7 Hz, H-26); ¹³C NMR (CDCl₃, 100 MHz) δ 185.3 (C, C-11), 150.9 (CH, C-13), 148.7 (CH, C-9), 127.3 (CH, C-12), 127.0 (CH, C-10), 109.1 (C, C-6), 79.7 (C, C-8), 65.3* (CH, C-2), 64.8* (CH, C-4), 39.1 (CH₂, C-5 and C-15), 37.9 (CH₂, C-3), 35.9 (CH₂, C-16), 34.1 (CH₂, C-14),

31.9 (CH₂, C-24), 29.6-29.7 (CH₂, C-18 to C-22), 29.3 (CH₂, C-23), 25.6 (CH₂, C-17), 22.7 (CH₂, C-25), 14.1 (CH₃, C-26) (*assignments are interchangeable); HRESIMS *m/z* 413.2672 [M+Na] (calcd for C₂₄H₃₈O₄Na, 413.2672).

Aculeatol E (5)

yellow oil; $[\alpha]_D^{22} +8.4$ (c 0.1, CHCl₃); UV (MeOH) $\lambda_{\max}$ (log ϵ) 221 (4.15) nm; IR (film) $\nu_{\max}$ 3441, 2921, 1670, 1637, 1080, 1014 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) and ¹³C NMR (CDCl₃, 100 MHz), see Table 1; HRESIMS *m/z* 459.3092 [M+Na] (calcd for C₂₆H₄₄O₅Na, 459.3086).

Amomol A (6)

amorphous white powder; $[\alpha]_D^{22} -11.4$ (c 0.4, CHCl₃); UV (MeOH) $\lambda_{\max}$ (log ϵ) 230 (4.16) nm; IR (film) $\nu_{\max}$ 3442, 2921, 2851, 1671, 1634, 1080, 1014 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) and ¹³C NMR (CDCl₃, 100 MHz), see Table 2; HRESIMS *m/z* 457.3294 [M+Na]⁺ (calcd for C₂₇H₄₆O₄Na, 457.3294).

Amomol B (7)

amorphous white powder; $[\alpha]_D^{22} +8.8$ (c 0.3, CHCl₃); UV (MeOH) $\lambda_{\max}$ (log ϵ) 230 (3.98) nm; IR (film) $\nu_{\max}$ 3442, 2917, 2850, 1673, 1634, 1081, 1017 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) and ¹³C NMR (CDCl₃, 100 MHz), see Table 2; HRESIMS *m/z* 457.3294 [M+Na] (calcd for C₂₇H₄₆O₄Na, 457.3294).

Preparation of Mosher Ester Derivatives of 6 and 7

The *R*-MTPA and *S*-MTPA esters of **6** and **7** were carried out by a convenient Mosher ester method described in the literature.¹⁵ **Compound 6a** [12-(*R*)-MTPA ester of **6**]: ¹H NMR (pyridine-*d*₅, 400 MHz) δ 6.958 (1H, H-10), 6.931 (1H, H-6), 6.310 (1H, H-9), 6.281 (1H, H-7), 5.533 (1H, m, H-12), 3.389 (3H, OCH₃), 2.613 (1H, H-11a), 2.191 (1H, H-11b), 1.818 (2H, H-13), 1.393-1.191 (CH₂), 0.874 (3H, H-27); HRESIMS *m/z* 650.3794 [M+Na]⁺ (calcd for C₃₇H₅₃F₃O₆, 650.3794). **Compound 6b** [12-(*S*)-MTPA ester of **6**]: ¹H NMR (pyridine-*d*₅, 400 MHz) δ 6.945 (1H, H-10), 6.878 (1H, H-6), 6.292 (1H, H-9), 6.273 (1H, H-7), 5.531 (1H, H-12), 3.284 (3H, OCH₃), 2.532 (1H, H-11a), 2.142 (1H, H-11b), 1.832 (2H, H-13), 1.391-1.182 (CH₂), 0.875 (3H, H-27); HRESIMS *m/z* 650.3794 [M+Na]⁺ (calcd for C₃₇H₅₃F₃O₆, 650.3794). **Compound 7a** [12-(*R*)-MTPA ester of **7**]: ¹H NMR (pyridine-*d*₅, 400 MHz) δ 6.964 (1H, H-10), 6.916 (1H, H-6), 6.311 (1H, H-9), 6.251 (1H, H-7), 5.549 (1H, H-12), 3.332 (3H, OCH₃), 2.358 (2H, H-11), 1.780 (2H, H-13), 1.486-1.152 (CH₂), 0.875 (3H, H-27); HRESIMS *m/z* 650.3794 [M+Na]⁺ (calcd for C₃₇H₅₃F₃O₆, 650.3794). **Compound 7b** [12-(*S*)-MTPA ester of **7**]: ¹H NMR (pyridine-*d*₅, 400 MHz) δ 6.963 (1H, H-10), 6.899 (1H, H-6), 6.304 (1H, H-9), 6.252 (1H, H-7), 5.487 (1H, H-12), 3.280 (3H, OCH₃), 2.355 (2H, H-11), 1.861 (2H, H-13), 1.481-1.198 (CH₂), 0.874 (3H, H-27); HRESIMS *m/z* 650.3794 [M+Na]⁺ (calcd for C₃₇H₅₃F₃O₆, 650.3794).

Preparation of 1a

Aculeatin A (**1**) (10 mg) was acetylated with acetic anhydride (0.5 mL) and pyridine (0.5 mL) at room temperature for 24 h. The reaction product was purified by preparative TLC using hexanes-acetone (2:1) to give aculeatin A 4-acetate (**1a**, 7.0 mg, R_f 0.7): ¹H NMR (CDCl₃, 400 MHz) δ 6.89 (1H, dd, *J* = 10.1, 3.0 Hz, H-13), 6.74 (1H, dd, *J* = 10.1, 3.0 Hz, H-9), 6.12 (1H, dd, *J* = 10.1, 2.0 Hz, H-12), 6.08 (1H, dd, *J* = 10.1, 2.0 Hz, H-10), 5.05 (1H, pentet, *J* = 2.8 Hz, H-4eq), 4.13 m (1H, H-2ax), 2.35 (1H, brt, *J* = 7.1 Hz, H-14a), 2.19 (1H, dd, *J* = 9.4, 7.1 Hz, H-15a), 2.14 (1H, td, *J* = 15.2, 2.3 Hz, H-5a), 2.00 (3H, s, COCH₃), 1.96 (1H, m, H-14b), 1.96 (1H, m, H-15b), 1.92 (1H, dd, *J* = 14.9, 3.8 Hz, H-5b), 1.76 (1H, brd, *J* = 14.2 Hz, H-3a),

1.47 (3H, m, H-16 and H-17a), 1.32 (1H, m, H-17b), 1.30 (1H, m, H-3b), 1.33-1.23 (22H, m, H-18 to H-27), 0.88 (3H, t, $J = 6.8$ Hz, H-28); ^{13}C NMR (CDCl_3 , 100 MHz) δ 185.8 (C, C-11), 171.2 (C, COO), 152.2 (CH, C-13), 149.8 (CH, C-9), 126.8 (CH, C-12), 126.6 (CH, C-10), 107.4 (C, C-6), 79.3 (C, C-8), 67.2 (CH, C-4), 65.5 (CH, C-2), 39.5 (CH_2 , C-15), 35.9 (CH_2 , C-5), 35.9 (CH_2 , C-16), 34.8 (CH_2 , C-3), 34.1 (CH_2 , C-14), 31.9 (CH_2 , C-26), 29.7-29.6 (CH_2 , C-18 to C-24), 25.6 (CH_2 , C-17), 29.4 (CH_2 , C-25), 22.7 (CH_2 , C-27), 21.5 (CH_3 , OCOCH_3), 14.1 (CH_3 , C-28); HRESIMS m/z 483.3083 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{28}\text{H}_{44}\text{O}_5\text{Na}$, 483.3080).

Preparation of 1b

Compound **1** (10 mg) was treated with diglycolic anhydride (10 mg) and pyridine (0.5 mL) at room temperature for 24 h. The reaction product was purified by preparative TLC (hexanes-EtOAc = 2:1) to give compound **1b** (7 mg, R_f 0.3): ^1H NMR (CDCl_3 , 400 MHz) δ 6.86 (1H), 6.74 (1H), 6.13 (1H), 6.09 (1H), 5.17 (1H), 4.10 (1H), 4.17 (4H), 2.35 (1H), 2.20 (1H), 2.20 (1H), 1.99 (1H), 1.99 (1H), 1.97 (1H), 1.80 (1H), 1.53 (1H), 1.48 (2H), 1.48 (1H), 1.34 (1H), 1.33-1.23 (20H), 0.88 (3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 185.9 (C), 172.5 (C), 170.5 (C), 151.9 (CH), 149.5 (CH), 127.0 (CH), 126.8 (CH), 107.2 (C), 79.3 (C), 68.8 (CH), 68.8 (CH_2) 65.5 (CH), 39.4 (CH_2), 35.8 (CH_2), 35.7 (CH_2), 34.6 (CH_2), 34.0 (CH_2), 31.9 (CH_2), 29.7-29.6 (CH_2), 29.4 (CH_2), 25.6 (CH_2), 22.7 (CH_2), 14.1 (CH_3); HRESIMS m/z 557.3109 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{30}\text{H}_{46}\text{O}_8\text{Na}$, 557.3085).

Preparation of 1c

Compound **1** (10 mg) was treated with (*S*)-campanoyl chloride (10 mg) and 4-(dimethylamino)pyridine (10 mg) in pyridine (1.0 mL) at room temperature for 48 h. The reaction product was purified by preparative TLC (hexanes-EtOAc = 2:1) to give compound **1c** (8 mg, R_f 0.5): ^1H NMR (CDCl_3 , 400 MHz) δ 6.86 (1H), 6.77 (1H), 6.15 (1H), 6.11 (1H), 5.23 (1H), 4.13 (1H), 2.39 (1H), 2.23 (1H), 2.18 (1H), 2.01 (1H), 1.99 (1H), 1.98 (1H), 1.84 (1H), 1.57 (1H), 1.47 (2H), 1.47 (1H), 1.33 (1H), 1.33-1.23 (20H), 1.06 (3H), 0.97 (3H), 0.92 (3H), 0.88 (3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 185.4 (C), 178.1 (C), 167.0 (C), 151.7 (CH), 149.3 (CH), 126.9 (CH), 126.5 (CH), 107.0 (C), 91.3 (C), 79.1 (C), 69.0 (CH), 65.4 (CH), 54.8 (C), 53.8 (C), 39.2, (CH_2), 35.9 (CH_2), 35.7 (CH_2), 34.6 (CH_2), 33.9 (CH_2), 31.9 (CH_2), 30.4 (CH_2), 29.6-29.5 (CH_2), 29.3 (CH_2), 28.7 (CH_2), 25.5 (CH_2), 22.6 (CH_2), 16.9 (CH_3), 16.8 (CH_3), 14.1 (CH_3), 9.6 (CH_3); HRESIMS m/z 621.3774 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{36}\text{H}_{54}\text{O}_7\text{Na}$, 621.3762).

Preparation of 1d

Compound **1** (10 mg) was treated with 2,6-dichloro-5-fluoropyridinecarbonyl chloride (15 mg), and 4-(dimethylamino)pyridine (10 mg) in pyridine at room temperature for 48 h. The reaction product was purified by preparative TLC (hexanes-EtOAc = 2:1) to give compound **1d** (9 mg, R_f 0.6): ^1H NMR (CDCl_3 , 400 MHz) δ 8.17 (1H), 6.90 (1H), 6.67 (1H), 6.19 (1H), 6.07 (1H), 5.40 (1H), 4.18 (1H), 2.43 (1H), 2.28 (1H), 2.18 (1H), 2.07 (1H), 2.03 (1H), 2.03 (1H), 1.91 (1H), 1.62 (1H), 1.50 (1H), 1.50 (1H), 1.34 (1H), 1.33-1.23 (20H), 0.88 (3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 185.4 (C), 161.5 (C), 154.9 (C), 152.3 (C), 150.9 (CH), 148.4 (CH), 127.4 (CH), 127.1 (CH), 107.6 (C), 79.2 (C), 69.4 (CH), 65.7 (CH), 39.3 (CH_2), 36.1 (CH_2), 35.8 (CH_2), 34.4 (CH_2), 33.9 (CH_2), 31.9 (CH_2), 29.7-29.6 (CH_2), 29.4 (CH_2), 25.6 (CH_2), 22.7 (CH_2), 14.1 (CH_3); HRESIMS m/z 632.2312 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{32}\text{H}_{42}\text{Cl}_2\text{FNO}_5\text{Na}$, 632.2316).

Preparation of 1e

Compound **1** (10 mg) was treated with tetrabromophthalic anhydride (15 mg) and 4-(dimethylamino)pyridine (10 mg) in pyridine (1.0 mL) at room temperature for 48 h. The reaction product was purified by preparative TLC (hexanes-EtOAc = 1:1) to give compound

1e (9 mg, R_f 0.4): ^1H NMR (CDCl_3 , 400 MHz) δ 6.80 (1H), 6.74 (1H), 6.04 (1H), 6.02 (1H), 5.18 (1H, m), 4.08 (1H), 2.32 (1H), 2.15 (2H), 2.00 (4H), 1.43-1.26 (26H), 0.878 (3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 185.6 (C), 169.7 (C), 166.6 (C), 151.9 (CH), 149.8 (CH), 138.0 (C), 135.3 (C), 133.4 (C), 130.6 (C), 129.9 (C), 128.5 (C), 126.9 (CH), 126.6 (CH), 106.7 (C), 79.5 (C), 71.4 (CH), 65.2 (CH), 39.4 (CH_2), 35.8 (CH_2), 34.3 (CH_2), 34.2 (CH_2), 31.9 (CH_2), 29.8-29.7 (CH_2), 29.4 (CH_2), 25.6 (CH_2), 22.7 (CH_2), 14.1 (CH_3); HRESIMS m/z 904.9512 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{34}\text{H}_{42}\text{Br}_4\text{O}_7\text{Na}$, 904.9520).

Preparation of 1f

Compound **1** (10 mg) was treated with tetrachlorophthalic anhydride (15 mg) and 4-(dimethylamino)pyridine (10 mg) in pyridine (1.0 mL) at room temperature for 24 h. The reaction product was purified by preparative TLC (hexanes-EtOAc = 1:1) to give compound **1f** (7 mg, R_f 0.4): ^1H NMR (CDCl_3 , 400 MHz) δ 6.81 (1H), 6.78 (1H), 6.06 (1H), 6.04 (1H), 5.24 (1H), 4.09 (1H), 2.33 (1H), 2.20 (2H), 2.08 (4H), 1.42-1.25 (26H), 0.88 (3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 185.6 (C), 169.6 (C), 166.6 (C), 152.0 (CH), 149.9 (CH), 134.3 (C), 132.0 (C), 130.7 (C), 126.9 (CH), 126.6 (CH), 122.2 (C), 121.7 (C), 106.8 (C), 79.6 (C), 71.3 (CH), 65.3 (CH), 39.5 (CH_2), 35.8 (CH_2), 35.7 (CH_2), 34.3 (CH_2), 31.9 (CH_2), 29.8-29.7 (CH_2), 29.4 (CH_2), 25.6 (CH_2), 22.7 (CH_2), 14.1 (CH_3); HRESIMS m/z 727.1562 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{34}\text{H}_{42}\text{Cl}_4\text{O}_7\text{Na}$, 727.1553).

Preparation of 1g

Compound **1** (20 mg) was treated with *p*-bromobenzoyl chloride (40 mg), 4-(dimethylamino)pyridine (20 mg) in pyridine (1.0 mL) at room temperature for 24 h. The reaction mixture was purified using silica gel column chromatography (hexanes-EtOAc = 3:1) to afford 18 mg of **1g**: ^1H NMR (CDCl_3 , 400 MHz) δ 7.76 (2H), 7.47 (2H), 6.94 (1H), 6.67 (1H), 6.16 (1H), 6.04 (1H), 5.39 (1H), 4.23 (1H), 2.38 (1H), 2.26 (1H), 2.05 (2H), 2.04 (1H), 2.04 (1H), 1.91 (1H), 1.58 (1H), 1.47 (2H), 1.47 (1H), 1.41 (1H), 1.33-1.23 (20H), 0.88 (3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 186.1 (C), 165.9 (C), 152.2 (CH), 149.9 (CH), 132.0 (CH), 131.6 (CH), 130.1 (C), 128.4 (C), 127.3 (CH), 127.0 (CH), 107.7 (C), 79.5 (C), 68.1 (CH), 66.1 (CH), 39.8 (CH_2), 37.0 (CH_2), 36.3 (CH_2), 35.1 (CH_2), 34.5 (CH_2), 32.3 (CH_2), 30.2-30.0 (CH_2), 29.7 (CH_2), 26.1 (CH_2), 23.1 (CH_2), 14.4 (CH_3); HRESIMS m/z 625.2335 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{33}\text{H}_{45}\text{BrO}_5\text{Na}$, 625.2328).

Preparation of 1h

Compound **1** (22 mg) was oxidized with pyridinium chlorochromate (40 mg) in CH_2Cl_2 -pyridine (1:1, 2 mL) at room temperature for 24 h. The reaction mixture was purified using silica gel column chromatography (dichloromethane) to yield 20 mg of **1h**: ^1H NMR (CDCl_3 , 400 MHz) δ 6.79 (1H), 6.75 (1H), 6.13 (1H), 6.11 (1H), 4.13 (1H), 2.77 (1H), 2.55 (1H), 2.42 (1H), 2.41 (1H), 2.40 (1H), 2.23 (1H), 2.11 (1H), 2.10 (1H), 1.66 (1H), 1.55 (1H), 1.38 (2H), 1.23-1.35 (20H), 0.88 (3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 204.5 (C), 185.2 (C), 50.3 (CH), 148.5 (CH), 127.5 (CH), 127.1 (CH), 109.5 (C), 79.7 (C), 69.6 (CH), 50.2 (CH_2), 47.2 (CH_2), 38.6 (CH_2), 36.1 (CH_2), 34.8 (CH_2), 31.8 (CH_2), 29.5-29.6 (CH_2), 29.3 (CH_2), 25.4 (CH_2), 22.6 (CH_2), 14.1 (CH_3); HRESIMS m/z 439.28276 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{26}\text{H}_{40}\text{O}_4\text{Na}$, 439.2819).

Preparation of 2a

Aculeatin B (**2**) (5.0 mg) was acetylated according to the same method described for **1a**, to give aculeatin B 4-acetate (**2b**, 2.5 mg): ^1H NMR (CDCl_3 , 400 MHz) δ 6.98 (1H, dd, J = 10.1, 3.0 Hz, H-13), 6.75 (1H, dd, J = 10.1, 3.0 Hz, H-9), 6.15 (1H, dd, J = 10.1, 2.0 Hz, H-12), 6.11 (1H, dd, J = 10.1, 2.0 Hz, H-10), 5.26 (1H, pentet, J = 3.0 Hz, H-4eq), 3.74 (1H, brt, J = 7.3 Hz, H-2ax), 2.63 (1H, dd, J = 12.9, 6.8 Hz, H-14a), 2.32 (1H, dt, J = 12.6, 7.6 Hz, H-15a), 2.09

(3H, s, COCH₃), 2.09 (1H, m, H-5a), 2.06 (1H, m, H-15b), 1.99 (1H, m, H-5b), 1.84 (1H, dd, $J = 12.9, 8.3$ Hz, H-14b), 1.73 (1H, brd, $J = 14.1$ Hz, H-3a), 1.61 (1H, m, H-16a), 1.54 (1H, m, H-3b), 1.48 (1H, m, H-17a), 1.47 (1H, m, H-16b), 1.32 (1H, m, H-17b), 1.33–1.23 (20H, m, H-18 to H-27), 0.88 (3H, t, $J = 6.8$ Hz, H-28); ¹³C NMR (CDCl₃, 100 MHz) δ 185.5 (C, C-11), 170.0 (C, COO), 151.9 (CH, C-13), 148.8 (CH, C-9), 127.2 (CH, C-10), 127.2 (CH, C-12), 108.2 (C, C-6), 77.8 (C, C-8), 70.1 (CH, C-2), 68.4 (CH, C-4), 37.5 (CH₂, C-5), 35.7 (CH₂, C-16), 35.2 (CH₂, C-15), 34.8 (CH₂, C-14), 34.7 (CH₂, C-3), 31.9 (CH₂, C-26), 29.7–29.6 (CH₂, C-18 to C-24), 29.4 (CH₂, C-25), 25.8 (CH₂, C-17), 22.7 (CH₂, C-27), 21.4 (CH₃, OCOCH₃), 14.1 (CH₃, C-28); HRESIMS m/z 483.3083 [M+ Na]⁺ (calcd for C₂₈H₄₄O₅Na, 483.3080).

Biological Evaluation

Chromatographic fractions were tested in the MCF-7 (human breast carcinoma) cell line during activity-guided fractionation. All isolates were assessed with the Lu1 (human lung carcinoma), LNCaP (hormone-dependent human prostate carcinoma), and MCF-7 cancer cell lines, using established protocols.^{15,16} Aculeatin (**1**) was evaluated in the in vivo hollow fiber model, using Lu1, LNCaP, and MCF-7 cells, according to a procedure described in the literature.^{20, 21} Aculeatin A (**1**) was tested further in the in vivo P388 murine lymphocytic leukemia model, as described previously.^{22,23} Finally, aculeatin A (**1**) has also evaluated in an in vivo human A2780 ovarian carcinoma murine xenograft model, performed according to a previously published protocol.^{24,25}

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

This work was supported by grants U19 CA52956 and P01CA125066-01A1 funded by the National Cancer Institute, NIH, Bethesda, MD. We are grateful to Drs. William C. Rose and Robert Wild, Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ, for the in vivo evaluation of aculeatin A (**1**). We thank the College of Pharmacy, The Ohio State University, for the provision of NMR spectroscopic equipment used in this investigation. We are grateful to Dr. Christopher M. Hadad, Department of Chemistry, and Mr. Paul Eichenseer of the Campus Chemical Instrument Center, The Ohio State University, for the mass spectrometric data.

References and Notes

1. Holdsworth KD, Mahana P. *Int. J. Crude Drug Res* 1983;21:121–133.
2. Heilmann J, Mayr S, Brun R, Rali T, Sticher O. *Helv. Chim. Acta* 2000;83:2939–2945.
3. Heilmann J, Brun R, Mayr S, Rali T, Sticher O. *Phytochemistry* 2001;57:1281–1285. [PubMed: 11454360]
4. Wong Y-S. *Chem. Commun* 2002:686–687.
5. Baldwin JE, Adlington RM, Sham VW-W, Marquez R, Bulger PG. *Tetrahedron* 2005;61:2353–2363.
6. Falomir E, Alvarez-Bercedo P, Carda M, Marco JA. *Tetrahedron Lett* 2005;46:8407–8410.
7. Alvarez-Bercedo P, Falomir E, Carda M, Marco JA. *Tetrahedron* 2006;62:9641–9649.
8. Chandrasekhar S, Rambabu C, Shyamsunder T. *Tetrahedron Lett* 2007;48:4683–4685.
9. Peuchmaur M, Wong Y-S. *J. Org. Chem* 2007;72:5374–5379. [PubMed: 17564466]
10. Salim A, Su B-N, Chai H-B, Riswan LBS, Ruskandi A, Farnsworth NR, Swanson SM, Kinghorn AD. *Tetrahedron Lett* 2007;48:1849–1853. [PubMed: 18320008]
11. Kinghorn AD, Farnsworth NR, Soejarto DD, Cordell GA, Swanson SM, Pezzuto JM, Wani MC, Wall ME, Oberlies NH, Kroll DJ, Kramer RA, Rose WC, Vite GD, Fairchild CR, Peterson RW, Wild R. *Pharm. Biol* 2003;41:53–67.
12. Dale JA, Mosher HS. *J. Am. Chem. Soc* 1973;95:512–519.
13. Kelly DR. *Tetrahedron: Asymmetry* 1999;10:2927–2934.

14. Seco JM, Quinoa E, Riguera R. *Tetrahedron: Asymmetry* 2001;12:2915–2925.
15. Su B-N, Park EJ, Mbwapbo ZH, Santarsiero BD, Mesecar AD, Fong HHS, Pezzuto JM, Kinghorn AD. *J. Nat. Prod* 2002;65:1278–1282. [PubMed: 12350147]
16. Likhitwitayawuid K, Angerhofer CK, Cordell GA, Pezzuto JM, Ruangrungsi N. *J. Nat. Prod* 1993;56:30–38. [PubMed: 8450319]
17. Seo E-K, Kim N-C, Mi Q, Chai H, Wall ME, Wani MC, Navarro HA, Burgess JP, Cabieses F, Tan GT, Farnsworth NR, Pezzuto JM, Kinghorn AD. *J. Nat. Prod* 2001;64:1481–1483.
18. Casciari JJ, Hollingshead MG, Alley MC, Mayo JG, Malspies L, Miyauchi S, Grever MR, Weinstein JN. *J. Natl. Cancer Inst* 1994;86:1864–1852.
19. Hollingshead MG, Alley MC, Camalier RF, Abbot BJ, Mayo JG, Malspeis L, Grever MR. *Life Sci* 1995;57:131–141. [PubMed: 7603295]
20. Mi Q, Lantvit D, Reyes-Lim E, Chai H, Zhao W, Lee I-S, Perez-Sanchez S, Ngassapa O, Kardono LBS, Hollingshead MG, Mayo JG, Farnsworth NR, Cordell GA, Kinghorn AD, Pezzuto JM. *J. Nat. Prod* 2002;65:842–850. [PubMed: 12088425]
21. Jones WP, Lobo-Echeverri T, Mi Q, Chai H-B, Soejarto DD, Cordell GA, Swanson SM, Kinghorn AD. *J. Nat. Prod* 2007;70:372–377. [PubMed: 17279798]
22. Rose WC, Schurig JE, Meeker JB. *Anticancer Res* 1988;8:355–368. [PubMed: 3389740]
23. Hwang BY, Su B-N, Chai H, Mi Q, Kardono LBS, Afriastini JJ, Riswan S, Santarsiero BD, Mesecar AD, Wild R, Fairfield CR, Vite GD, Rose WC, Farnsworth NR, Cordell GA, Pezzuto JM, Swanson SM, Kinghorn AD. *J. Org. Chem* 2004;69:3350–3358. [PubMed: 15132542]
24. Rose WC, Basler GA. *In Vivo* 1991;4:391–396. [PubMed: 2103379]
25. Rose WC, Crosswell AR, Schurig JE, Casazza AM. *Cancer. Chemother. Pharmacol* 1993;32:197–203. [PubMed: 8500224]

Figure 1.
Key NOESY correlations of **3**

Figure 2.

Effect of aculeatin A (**1**) on the growth of MCF-7 cells in the hollow fiber assay. Hollow fibers containing either Lu1, LNCaP, or MCF-7 cells were propagated subcutaneously (SC) or within the peritoneum (IP) of immunodeficient mice. The animals were treated with vehicle or aculeatin A (**1**) once daily by intraperitoneal injection (6.25, 12.5, 25, 50 mg/kg) from days 3–6 after implantation.

R

R

1a Ac **1h** **2a**

Table 1
¹H and ¹³C NMR Spectroscopic Data for Compounds **3** and **5**

aculeatin E (3)			aculeatol (5)	
position	δ _C , mult. ^a	δ _H (J in Hz)	δ _C , mult. ^a	δ _H (J in Hz)
2	71.6, CH	3.36, m	69.7, CH	3.91, m
3	40.8, CH ₂	1.96, m	37.8, CH ₂	1.61, m
		1.23, m		1.51, m
4	66.8, CH	3.85, tt (11.2, 4.4)	65.3, CH	4.38, m
5	43.5, CH ₂	2.12, m	40.3, CH ₂	2.03, dd (13.9, 3.1)
		1.78, m		1.86, m
6	109.2, qC		106.7, qC	
8	78.0, qC		81.9, qC	
9	148.9, CH	6.79, dd (10.0, 2.9)	69.7, CH	3.93, dd (8.7, 5.4)
10	127.1, CH	6.13, dd (10.0, 1.8)	44.2, CH ₂	2.73, m
11	185.5, qC		198.6, qC	
12	127.3, CH	6.14, dd (10.4, 1.8)	129.6, CH	5.99, d (10.0)
13	151.6, CH	6.99, dd (10.4, 2.9)	148.0, CH	6.61, d (10.0)
14	34.9, CH ₂	2.28, m	31.7, CH ₂	2.52, dd (11.7, 8.2)
		2.06, m		1.86, m
15	33.3, CH ₂	2.39, m	34.6, CH ₂	2.65, dd (12.2, 8.2)
		1.83, m		1.87, m
16	35.7, CH ₂	1.62, m,	35.7, CH ₂	1.57, m
		1.52, m		1.44, m
17	25.8, CH ₂	1.47, m	25.5, CH ₂	1.44, m
		1.31, m		1.30, m
18–25	29.3–29.6, CH ₂	1.26–1.30, m	29.4–29.7, CH ₂	1.23–1.30, m
26	31.9, CH ₂	1.28, m	31.9, CH ₂	1.23–1.30, m
27	22.6, CH ₂	1.28, m	22.7, CH ₂	1.26, m
28	14.1, CH ₃	0.88, t (6.6)	14.1, CH ₃	0.89, t (7.0)

^aMultiplicity was deduced from the DEPT and HSQC spectroscopic data.

Table 2
 ^1H and ^{13}C NMR Spectroscopic Data for Compounds **6** and **7**

amomol A (6)			amomol B (7)	
position	δ_{C} , mult. ^a	δ_{H} (<i>J</i> in Hz)	δ_{C} , mult. ^a	δ_{H} (<i>J</i> in Hz)
2	111.6, qC		111.5	
3	36.6, CH ₂	2.34, m	36.6	2.24, m
		2.15, m		
4	34.9, CH ₂	2.39, m	35.1	2.43, m
		2.07, m		2.07, m
5	79.1, qC		78.7	
6	148.4, CH	6.78, d (10.0, 2.7)	148.2	6.81, d (10.0)
7	127.1, CH	6.13, d (10.0)	127.4 ^b	6.14, d (10.0)
8	185.2, qC		185.3	
9	127.7, CH	6.17, d (10.0)	127.5 ^b	6.17, d (10.5)
10	150.6, CH	6.85, d (10.0, 2.7)	150.6	6.85, d (10.5)
11	40.7, CH ₂	2.13, m	40.1	1.96, m
		1.70, brd (14.7)		1.96, m
12	69.1, CH	3.84, m	68.2	3.79, m
13	37.8, CH ₂	1.54, m	37.8	1.53, m
		1.43, m		1.43, m
14	25.4, CH ₂	1.43, m	25.5	1.43, m
		1.33, m		1.33, m
15–24	29.6–29.7, CH ₂	1.26–1.33, m	29.6–29.7	1.26–1.33, m
25	31.9, CH ₂	1.26, m	31.9	1.26, m
26	22.7, CH ₂	1.30, m	22.7	1.30, m
27	14.1, CH ₃	0.88, t (6.8)	14.1	0.89, t (6.7)
OCH ₃	48.9, CH ₃	3.35, s	48.5	3.35, s

^a Multiplicity was deduced from the DEPT and HSQC spectroscopic data.

^b Assignments are interchangeable.

Table 3
Cytotoxicity Data of Compounds **1**, **1a–1h**, **2**, **2a**, and **3–7**

compound	cell line, ^{ab}		
	Lu1	LNCaP	MCF-7
1	1.0	0.5	0.2
1a	2.6	1.1	1.5
1b	3.4	1.9	1.3
1c	4.0	3.0	3.2
1d	22.2	17.9	14.6
1e	10.3	5.1	4.7
1f	12.8	5.8	4.8
1g	1.3	0.8	0.7
1h	30.5	22.1	7.5
2	3.1	1.2	1.9
2a	5.7	2.2	3.5
3	1.8	1.8	0.5
4	1.0	0.7	0.5
5	1.8	4.4	3.9
6	0.9	0.7	0.9
7	0.5	0.9	0.7

^a Results are expressed as ED₅₀ values (μM), and values < 10 μM are considered to be active.

^b Key to cell lines used: Lu1 (human lung carcinoma); LNCaP (hormone-dependent human prostate carcinoma); MCF-7 (human breast carcinoma).